Andrea J Rapkin1. 1. Department of Obstetrics and Gynecology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-1740, USA. arapkin@mednet.ucla.edu
Abstract
OBJECTIVE: The decline in concentrations of gonadal hormones during menopause gives rise to a range of physiologic and psychologic changes that may impact a woman's health and quality of life significantly. Most notable among these are vasomotor symptoms (hot flashes and night sweats) and mood and sleep disturbances. STUDY DESIGN: This article reviews the physiologic condition underlying menopausal vasomotor symptoms and centrally active, nonhormonal therapies that have demonstrated efficacy for their treatment. RESULTS: Despite the emergence of a range of nonhormonal treatments for vasomotor symptoms, a need still exists for safe and effective therapeutic options that directly target the underlying thermoregulatory mechanisms for women who want treatment but prefer to avoid hormone therapy or for whom hormone therapy is contraindicated. CONCLUSION: The availability of centrally active therapies for menopausal vasomotor symptoms with risks and benefits clearly defined by results from well-designed clinical trials has the potential to allay safety concerns that are associated with the treatment of these common symptoms.
OBJECTIVE: The decline in concentrations of gonadal hormones during menopause gives rise to a range of physiologic and psychologic changes that may impact a woman's health and quality of life significantly. Most notable among these are vasomotor symptoms (hot flashes and night sweats) and mood and sleep disturbances. STUDY DESIGN: This article reviews the physiologic condition underlying menopausal vasomotor symptoms and centrally active, nonhormonal therapies that have demonstrated efficacy for their treatment. RESULTS: Despite the emergence of a range of nonhormonal treatments for vasomotor symptoms, a need still exists for safe and effective therapeutic options that directly target the underlying thermoregulatory mechanisms for women who want treatment but prefer to avoid hormone therapy or for whom hormone therapy is contraindicated. CONCLUSION: The availability of centrally active therapies for menopausal vasomotor symptoms with risks and benefits clearly defined by results from well-designed clinical trials has the potential to allay safety concerns that are associated with the treatment of these common symptoms.
Authors: Alan J Conley; Frank Z Stanczyk; John H Morrison; Pawel Borowicz; Kurt Benirschke; Nancy A Gee; Bill L Lasley Journal: Menopause Date: 2013-03 Impact factor: 2.953
Authors: Katherine M Newton; Susan D Reed; Louis C Grothaus; Andrea Z La Croix; Larissa Nekhlyudov; Kelly Ehrlich; Evette J Ludman Journal: Menopause Date: 2010-07 Impact factor: 2.953
Authors: Troy A Roepke; Martha A Bosch; Elizabeth A Rick; Benjamin Lee; Edward J Wagner; Dana Seidlova-Wuttke; Wolfgang Wuttke; Thomas S Scanlan; Oline K Rønnekleiv; Martin J Kelly Journal: Endocrinology Date: 2010-08-04 Impact factor: 4.736
Authors: Thomas Rampp; Linda Tan; Lin Zhang; Zhuo-Jun Sun; Petra Klose; Frauke Musial; Gustav Jürgen Dobos Journal: Chin J Integr Med Date: 2008-10-14 Impact factor: 1.978